{Reference Type}: Journal Article
{Title}: Respiratory support with standard low-flow oxygen therapy, high-flow oxygen therapy or continuous positive airway pressure in adults with acute hypoxaemic respiratory failure in a resource-limited setting: protocol for a randomised, open-label, clinical trial - the Acute Respiratory Intervention StudiEs in Africa (ARISE-AFRICA) study.
{Author}: Kwizera A;Kabatoro D;Owachi D;Kansiime J;Kateregga G;Nanyunja D;Sendagire C;Nyakato D;Olaro C;Audureau E;Mekontso Dessap A;
{Journal}: BMJ Open
{Volume}: 14
{Issue}: 6
{Year}: 2024 Jul 1
{Factor}: 3.006
{DOI}: 10.1136/bmjopen-2023-082223
{Abstract}: <B>BACKGROUND: </B>Acute hypoxaemic respiratory failure (AHRF) is associated with high mortality in sub-Saharan Africa. This is at least in part due to critical care-related resource constraints including limited access to invasive mechanical ventilation and/or highly skilled acute care workers. Continuous positive airway pressure (CPAP) and high-flow oxygen by nasal cannula (HFNC) may prove useful to reduce intubation, and therefore, improve survival outcomes among critically ill patients, particularly in resource-limited settings, but data in such settings are lacking. The aim of this study is to determine whether CPAP or HFNC as compared with standard oxygen therapy, could reduce mortality among adults presenting with AHRF in a resource-limited setting.<BR><B>METHODS: </B>This is a prospective, multicentre, randomised, controlled, stepped wedge trial, in which patients presenting with AHRF in Uganda will be randomly assigned to standard oxygen therapy delivered through a face mask, HFNC oxygen or CPAP. The primary outcome is all-cause mortality at 28 days. Secondary outcomes include the number of patients with criteria for intubation at day 7, the number of patients intubated at day 28, ventilator-free days at day 28 and tolerance of each respiratory support.<BR><B>BACKGROUND: </B>The study has obtained ethical approval from the Research and Ethics Committee, School of Biomedical Sciences, College of Health Sciences, Makerere University as well as the Uganda National Council for Science and Technology. Patients will be included after informed consent. The results will be submitted for publication in peer-reviewed journals.<BR><B>BACKGROUND: </B>NCT04693403.<BR><B>METHODS: </B>8 September 2023; version 5.